Skip to main content
STME logo

STIMCELL ENERGETICS INC. (STME) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.30 $0.00 (0.00%)
MCap: $6.34M| Vol: 5.0K|

Market cap $6.34M is the value of all shares combined.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

STIMCELL ENERGETICS INC. (STME) trades at $0.30. Stimcell Energetics, Inc. (STME) is a biotechnology company focused on developing therapeutic and non-therapeutic solutions for various health conditions. Market cap: $6.34M, Sector: Healthcare.

Price as of · Last analyzed: Jun 14, 2026
Stimcell Energetics, Inc. (STME) is a biotechnology company focused on developing therapeutic and non-therapeutic solutions for various health conditions. Its primary product, the eBalance system, targets pain relief and wellness, catering to a growing market in the healthcare sector.

Analyst Coverage for STME: STME does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • MDT · Medtronic plc · 81 /100
  • SYK · Stryker Corporation · 80 /100
  • BSX · Boston Scientific Corporation · 77 /100

See all scored stocks →

STIMCELL ENERGETICS INC. (STME) Healthcare & Pipeline Overview

CEODavid Jeffs
Employees1
HeadquartersVancouver, CA
IPO Year2013

Stimcell Energetics, Inc. (STME) specializes in innovative biotechnology solutions, particularly the eBalance system, designed to enhance wellness and manage chronic health conditions, positioning itself within the expanding medical devices sector.

Data Provenance | Financial Data Quantitative Analysis Analysis: Jun 14, 2026

What Is the Investment Thesis for STME?

AI-written as of Jun 14, 2026 — figures and tone reflect the data available then, not today's score.

Stimcell Energetics, Inc. is positioned in a niche segment of the healthcare market, focusing on innovative pain management solutions through its eBalance system. The company operates in a sector projected to grow as the demand for non-invasive therapeutic devices increases, driven by an aging population and a rise in chronic health conditions. Key value drivers include the unique microcurrent technology utilized in the eBalance system, which differentiates it from traditional pain relief methods. Additionally, the company's rebranding and focus on market introduction suggest a strategic pivot towards enhancing its visibility and market penetration. However, risks include the challenges of operating as an OTC stock, which may limit access to capital and increase scrutiny from investors. The success of Stimcell Energetics will heavily rely on its ability to secure funding for product development and marketing efforts within the competitive medical devices landscape.

Based on FMP financials and quantitative analysis

STME Key Highlights

AI-written as of Jun 14, 2026 — figures and tone reflect the data available then, not today's score.

Market Cap of $6.34M indicates a small but focused presence in the medical devices sector.

  • Beta of 48.49 suggests high volatility, reflecting the risks associated with OTC market listings.
  • No dividend yield, indicating a focus on reinvestment in product development rather than shareholder returns.
  • Single employee structure may limit operational capacity but allows for streamlined decision-making.
  • The eBalance system targets a wide range of health conditions, potentially appealing to a diverse customer base.

Who Are STME's Competitors?

STME is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
MDT Medtronic plc $100.72 -1.56% $129B 81 5-pillar
SYK Stryker Corporation $317.54 +2.19% $121B 80 5-pillar
BSX Boston Scientific Corporation $43.64 +1.42% $63.3B 77 5-pillar
AEMD Aethlon Medical, Inc. $5.11 +0.59% $8.21M 31 5-pillar
HYPD Hyperion DeFi, Inc. $2.38 -0.21% $36.2M 39 5-pillar
LNSR LENSAR, Inc. $4.85 -1.22% $59.6M 44 5-pillar
HSDT Solana Company $1.63 -0.31% $103M 43 5-pillar
APYX Apyx Medical Corporation $2.49 -2.54% $105M 33 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are STME's Key Strengths?

Innovative product offering with the eBalance system targeting multiple health conditions.

  • Small team allows for flexibility and rapid decision-making.
  • Established brand identity following rebranding efforts.

What Are STME's Weaknesses?

Limited operational capacity with only one employee.

  • Small market capitalization may limit growth potential.
  • Lack of established distribution channels compared to larger competitors.

What Could Drive STME Stock Higher?

Expansion of marketing efforts for the eBalance system to increase product visibility.

  • Development and refinement of the eBalance product line to meet market demands.
  • Potential partnerships with healthcare providers to enhance distribution channels.
  • Monitoring of industry trends to adapt product offerings accordingly.

What Are the Key Risks for STME?

Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.

  • Regulatory challenges in introducing new products to the market.
  • High volatility associated with OTC market trading.
  • Competition from established medical device companies with greater resources.
  • Limited operational capacity may hinder growth opportunities.

What Are the Growth Opportunities for STME?

  • Expansion of eBalance System: The eBalance system is designed to cater to a growing market of individuals seeking alternative pain management solutions. The global pain management market is projected to reach $85 billion by 2027, with increasing demand for non-pharmaceutical options. Stimcell Energetics can capitalize on this trend by expanding its marketing efforts and increasing product availability in healthcare settings.
  • Partnerships with Healthcare Providers: Collaborating with healthcare practitioners can enhance the credibility and reach of the eBalance system. By establishing partnerships with clinics and hospitals, Stimcell Energetics can facilitate product trials and gain endorsements from healthcare professionals, driving adoption and sales. This strategy could significantly increase market penetration over the next 2-3 years.
  • Development of New Product Lines: Stimcell Energetics has the opportunity to innovate further within the medical devices sector by expanding its product offerings beyond the eBalance system. Developing complementary products that address other health conditions could tap into additional market segments, potentially increasing revenue streams over the next 5 years.
  • Increased Focus on Wellness: As consumer awareness of health and wellness grows, there is a rising demand for products that promote overall well-being. Stimcell Energetics can leverage this trend by marketing the eBalance Home System as part of a holistic wellness approach, appealing to health-conscious consumers looking for non-invasive solutions.
  • Geographic Expansion: Stimcell Energetics could explore international markets, particularly in regions with a high prevalence of chronic diseases and a growing acceptance of alternative therapies. Entering markets in Europe and Asia could provide substantial growth opportunities, with the potential to increase sales and brand recognition in the next 3-5 years.

What Are STME's Competitive Advantages?

  • Unique microcurrent technology differentiates the eBalance system from competitors.
  • Focus on both clinical and home-use applications provides a broader market appeal.
  • Established brand recognition following rebranding efforts enhances market positioning.
  • Small operational structure allows for agile decision-making and innovation.
  • Targeting a growing segment of health-conscious consumers seeking non-invasive solutions.

What Does STME Do?

StimCell Energetics Inc., established in 2010 as Cell MedX Corp., is a biotechnology firm headquartered in Vancouver, Canada. The company focuses on the research, development, and market introduction of therapeutic and non-therapeutic solutions aimed at individuals managing chronic conditions such as diabetes, Parkinson's disease, hypertension, neuropathy, and kidney function issues. In November 2024, the company rebranded to its current name, reflecting its commitment to energizing health solutions. Its flagship product, the eBalance system, consists of two versions: the eBalance Pro System for clinical use by healthcare practitioners and the eBalance Home System for personal use. Both systems operate through the eBalance Console, which features three pre-programmed microcurrent algorithms targeting general wellness, pain relief, and a dual mode for combined benefits. These products aim to provide temporary relief from discomfort in various body areas, including the shoulders, waist, back, neck, arms, and legs. With a small team of just one employee, StimCell Energetics is positioned to leverage its innovative technology in a growing market, addressing the needs of patients seeking alternative solutions for pain management and overall health improvement.

What Products and Services Does STME Offer?

  • Develop therapeutic and non-therapeutic solutions for chronic health conditions.
  • Offer the eBalance system for pain relief and overall wellness.
  • Provide both clinical and home-use versions of their flagship product.
  • Utilize microcurrent technology to promote health benefits.
  • Target conditions such as diabetes, Parkinson's disease, and hypertension.
  • Focus on innovative biotechnology solutions in the medical devices sector.

How Does STME Make Money?

  • Generate revenue through the sale of eBalance systems to healthcare practitioners and consumers.
  • Leverage partnerships with healthcare providers for product distribution.
  • Focus on direct-to-consumer sales for the eBalance Home System.
  • Explore potential licensing agreements for proprietary technology.
  • Invest in research and development to enhance product offerings and expand market reach.

What Industry Does STME Operate In?

The medical devices industry is experiencing significant growth, driven by advancements in technology and an increasing prevalence of chronic diseases. The global market for medical devices is projected to reach over $600 billion by 2028, with a compound annual growth rate (CAGR) of approximately 5.4%. Within this landscape, companies like Stimcell Energetics, which focus on innovative therapeutic solutions, are well-positioned to capture market share. The competitive landscape includes both established players and emerging startups, emphasizing the need for differentiation through unique product offerings and effective marketing strategies.

Who Are STME's Key Customers?

  • Healthcare practitioners seeking innovative pain management solutions for their patients.
  • Individuals managing chronic health conditions looking for alternative therapies.
  • Wellness-focused consumers interested in non-invasive health solutions.
  • Clinics and hospitals looking to incorporate new therapeutic technologies.
  • Potential international markets with demand for alternative medical devices.
Model self-rating on this text: 65% (not a measure of the evidence) Updated: Jun 14, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● Price is current
  • ● No filing on record
  • ● No analyst coverage
ROE 46%

Key Financial Metrics

Return on equity for STIMCELL ENERGETICS INC. stands at 45.7%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -5.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.02 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -15.2%, the inverse of the P/E and a quick read on earnings relative to price.

STIMCELL ENERGETICS INC. (STME) Valuation Context

Valued at $6.34M, STME is classified as a micro-cap stock.

Company Profile

STIMCELL ENERGETICS INC. operates in the Healthcare sector. It is headquartered in Vancouver, Canada.

F-Score 1/9

Financial Health

STIMCELL ENERGETICS INC.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

FY2026 est

Forward Outlook

Wall Street analysts project STIMCELL ENERGETICS INC. revenue of about $0 for fiscal 2026, with EPS near $-0.04.

Net buying

Insider Activity

12 transactions · 3 purchases, 0 sales, 9 other transactions · 5 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

STME Financials

Bull Case vs Bear Case

Bull Case

  • Innovative product offering with the eBalance system targeting multiple health conditions.
  • Small team allows for flexibility and rapid decision-making.
  • Established brand identity following rebranding efforts.
  • Upcoming: Expansion of marketing efforts for the eBalance system to increase product visibility.

Bear Case

  • Limited operational capacity with only one employee.
  • Small market capitalization may limit growth potential.
  • Lack of established distribution channels compared to larger competitors.
  • Potential: Regulatory challenges in introducing new products to the market.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026

STME Latest News

STME Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for STME.

Price Targets

Wall Street price target analysis for STME.

STME MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for STME; grades run from A+ (80-100) to F (below 30).

Leadership: David Jeffs

CEO

David Jeffs has been leading Stimcell Energetics, Inc. since its inception in 2010, bringing extensive experience in the biotechnology sector. He has a background in both science and business, which has equipped him with the skills necessary to navigate the complex landscape of medical devices. Jeffs has a proven track record in product development and market introduction, having successfully transitioned the company from its original identity as Cell MedX Corp. to its current focus on innovative health solutions.

Track Record: Under David Jeffs' leadership, Stimcell Energetics has rebranded and positioned itself to capture a growing market in the healthcare sector. His strategic decisions have focused on enhancing product visibility and expanding the company's reach within therapeutic markets.

STME OTC Market Information

The OTC Other tier indicates that Stimcell Energetics, Inc. operates in a less regulated environment compared to major exchanges like NYSE or NASDAQ. This tier is characterized by lower reporting requirements, which can lead to increased risk for investors due to less transparency and oversight.

  • OTC Tier: OTC Other
Liquidity: Trading volume for OTC stocks can be significantly lower than that of stocks listed on major exchanges, which may lead to wider bid-ask spreads and potential challenges in executing trades at desired prices. Investors may experience difficulties in buying or selling shares quickly.
OTC Risk Factors:
  • Limited regulatory oversight may expose investors to higher risks.
  • Potential for lower liquidity compared to stocks on major exchanges.
  • Increased scrutiny from investors due to the company's small size and operational capacity.
Due Diligence Checklist:
  • Verify the company's financial health and recent performance.
  • Examine the product pipeline and development timelines.
  • Assess the competitive landscape and market positioning.
  • Research management's track record and strategic vision.
  • Evaluate potential risks associated with OTC trading.
Legitimacy Signals:
  • Established history since 2010, indicating operational stability.
  • Recent rebranding efforts to enhance market presence.
  • Focus on innovative solutions in a growing healthcare market.

STIMCELL ENERGETICS INC. Healthcare Stock: Key Questions Answered

Is STME a good stock to buy?

Stock Expert AI does not rate STME buy, sell or hold. STIMCELL ENERGETICS INC. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the STME stock price today?

The last price recorded on this page for STIMCELL ENERGETICS INC. (STME) is $0.30, as of the Nov 18, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for STME?

Stimcell Energetics, Inc. faces several risks, including the challenges of operating as an OTC stock, which may limit access to capital and increase scrutiny from investors.

What are the key factors to evaluate for STME?

Evaluate STME on fundamentals, analyst consensus, and risk factors. Stimcell Energetics, Inc. is positioned in a niche segment of the healthcare market, focusing on innovative pain management solutions through its eBalance system. Not financial advice.

How frequently does STME data refresh on this page?

STME's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven STME's recent stock price performance?

STIMCELL ENERGETICS INC. (STME) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product offering with the eBalance system targeting multiple health conditions. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider STME overvalued or undervalued right now?

STIMCELL ENERGETICS INC. (STME) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research STME before investing?

Before investing in STIMCELL ENERGETICS INC. (STME), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Limited financial disclosures available due to OTC classification.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives